Published 4 days ago • loading... • Updated 3 days ago

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

On Monday, Bausch + Lomb Board of Directors Chairman Thomas J. Appio was appointed interim CEO, replacing Brent Saunders following a mutual agreement with the board.
Preliminary third-quarter results support an expected increase in 2026 adjusted EBITDA guidance for Bausch + Lomb and Bausch Health Companies Inc., based on strong business performance.
U.S.-Listed Bausch + Lomb shares fell more than 7% during Monday's trading, while Citi analysts said the change "seems sudden" but Appio's experience positions him well for transition.
Appio will continue serving as Bausch Health CEO while assuming interim leadership of Bausch + Lomb, having previously headed the company's international business from 2016 to 2022.
The companies remain in a blackout period and will provide additional financial details when reporting third-quarter results on October 28, with full guidance updates expected then.

Insights by Ground AI

14 Articles

finchannel.com

Center

Bausch + Lomb shares fall as CEO Saunders departs - FINCHANNEL

Bausch + Lomb shares fall as CEO Saunders departs

4 days ago

Read Full Article

Pharmaphorum

Center

Brent Saunders ejects from Bausch + Lomb once again

Brent Saunders' second stint as chief executive of eye care company Bausch + Lomb has come to an end.

4 days ago

Read Full Article

Reuters

+2 Reposted by 2 other sources

Center

Bausch + Lomb CEO Saunders departs, Chairman Appio named interim chief ...

4 days ago·London, United Kingdom

Read Full Article

Rutland Herald

+2 Reposted by 2 other sources

Center

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance

VAUGHAN, Ontario--(BUSINESS WIRE)--Oct 12, 2026-

4 days ago

Read Full Article

biopharmadive.com

Center

Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

Bausch and Brent Saunders “mutually agreed” on his exit from the company, according to a statement. Elsewhere, Tezspire could have a new edge on Dupixent and a recent buyout deal paid dividends.

4 days ago

Read Full Article

GeneOnline News

Bausch + Lomb Appoints Thomas Appio Interim CEO Amid Upward Revision of Financial Guidance

Bausch + Lomb appointed Thomas Appio as its interim chief executive officer on Monday, a leadership change that coincides with the company’s announcement of an expected upward revision to its full-year financial guidance. The transition in executive management occurs as the eye health company prepares to adjust its performance projections for the remainder of the fiscal year. The company confirmed the appointment in a brief statement, noting tha…

3 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year